Comparison of the efficacy of thalidomide combined with low-dose rituximab and low-dose rituximab alone in the treatment of steroid-resistant/refractory adult patients with primary immune thrombocytopenia: an open-label trial.

Front Med (Lausanne) · 2025 · PMC12827102 · PMID 41585259

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

a nonsignificant trendp > 0.05actually significant

In the ctrl-group, a nonsignificant trend toward lower NK cell counts was observed in the NR subgroup compared to the CR and PR subgroups ( p > 0.05).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.